Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2008

01-06-2008 | Abstract

30th Annual San Antonio Breast Cancer Symposium Late Breaking Abstracts

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Login to get access

Excerpt

Objectives: The 21-gene Recurrence Score assay (RS) is prognostic for women with node-negative, ER-positive breast cancer (BC) treated with tamoxifen (T) alone and a high RS predicts a large, additional chemotherapy benefit. There are no data in a node-positive population with a T-alone control. The 2 primary objectives of this analysis were to determine if the RS (1) provides prognostic data for DFS in the T-alone control arm and (2) predicts a group that does not benefit from chemotherapy followed by T, despite positive nodes. …
Metadata
Title
30th Annual San Antonio Breast Cancer Symposium Late Breaking Abstracts
Publication date
01-06-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9981-9

Other articles of this Issue 3/2008

Breast Cancer Research and Treatment 3/2008 Go to the issue

Clinical Trial

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen

Clinical Trial

A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer

Letter to the Editor

Identification of rare complete BRCA1 gene deletion using a combination of SNP haplotype analysis, MLPA and array-CGH techniques

Epidemiology

NSAID use and breast cancer risk in the VITAL cohort

Review

259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up

Epidemiology

Parity and disparity in first course treatment of invasive breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits